Clinically Significant Outcomes, Disease Burden, Treatment and Management in Fibrosing Interstitial Lung Disease in Japan- A National Database Study

Clinically Significant Outcomes, Disease Burden, Treatment and Management in Fibrosing Interstitial Lung Disease in Japan- A National Database Study - Fibrosing ILD-related clinically significant outcomes in Japan - A National Database Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059748

Enrollment

200000

Registered

2025-12-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IPF, PPF, and non-progressive ILD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with at least 2 fibrosing ILD codes in different months during the patient identification period Patients aged 20 years or older on the index date Patients for whom data for the 12 months prior to the index date can be extracted as baseline data

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To investigate the cumulative incidences of clinically significant outcomes such as mortality (including lung transplantation), all cause hospitalisation, respiratory hospitalisation, and acute exacerbation in patients with fibrosing ILDs in Japan.	—

Secondary

Measure	Time frame
To describe baseline demographic and clinical characteristics in patients with fibrosing ILDs in Japan. To describe the distribution of PPF progression proxies met in patients with progression to PPF. To describe healthcare resource utilisation (HCRU) and medical cost in patients with fibrosing ILDs in Japan. To describe clinical practice on treatment and management in patients with fibrosing ILDs in Japan.	—

Measure

Time frame

To describe baseline demographic and clinical characteristics in patients with fibrosing ILDs in Japan. To describe the distribution of PPF progression proxies met in patients with progression to PPF. To describe healthcare resource utilisation (HCRU) and medical cost in patients with fibrosing ILDs in Japan. To describe clinical practice on treatment and management in patients with fibrosing ILDs in Japan.

—

Countries

Japan

Contacts

Public ContactTomohiro Ito

Nippon Boehringer Ingelheim Co., Ltd. Medicine Division

tomohiro.ito@boehringer-ingelheim.com03-6417-2780

Outcome results